Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...
One of these players has split its stock in the past. The other one hasn't.
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...
SNY earnings call for the period ending September 30, 2024.
Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2% on...
For Immediate ReleaseChicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...
Let's look beyond this piece of bad news from regulators.
This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s PFE gene therapy for hemophilia,...